Galmed Unveils Brain-Penetrating Formulation of Aramchol Targeting Neurological Disorders

Galmed Pharmaceuticals has announced a breakthrough in developing a novel brain-penetrating formulation of its SCD1 inhibitor, Aramchol. The new formulation is designed to cross the blood-brain barrier, expanding the therapeutic potential of Aramchol beyond liver diseases into neurological indications. This advancement represents a significant step in leveraging metabolic pathways for treating central nervous system disorders, with preclinical studies demonstrating promising brain exposure and activity.

Advancing SCD1 Inhibition into Neurology

The new formulation enables Aramchol to effectively reach brain tissue, addressing a long-standing challenge in drug delivery for neurological conditions. By targeting stearoyl-CoA desaturase-1 (SCD1), the therapy may influence lipid metabolism in the brain, which is increasingly linked to neurodegenerative diseases. This development opens new research avenues for conditions where metabolic dysfunction plays a critical role.

Strategic Expansion Beyond Liver Disease

Originally developed for non-alcoholic steatohepatitis (NASH), Aramchol’s repositioning reflects Galmed’s broader strategy to diversify its pipeline. Entering the neurology space could significantly enhance the drug’s commercial and clinical value. The move also aligns with growing industry interest in multi-indication therapies that target underlying metabolic mechanisms across different disease areas.